Kenneth B Simon

US Patent:

7465449, Dec 16, 2008

Filed:

Mar 13, 2003

Appl. No.:

10/507662

Inventors:

Shelia M. Violette - Lexington MA, US
Paul H. Weinreb - Andover MA, US
Kenneth J. Simon - Cambridge MA, US
Dean Sheppard - Oakland CA, US
Diane R. Leone - Winchester MA, US

Assignee:

Biogen Idec MA Inc. - Cambridge MA
The Regents of the University of California - Oakland CA

International Classification:

A61K 39/395
G01N 33/53
C07K 16/28

US Classification:

4241431, 435 71, 53038822, 5303871

Abstract:

Monoclonal antibodies that specifically bind to M. 96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Qmediated diseases.

US Patent:

7678371, Mar 16, 2010

Filed:

Mar 6, 2006

Appl. No.:

11/369641

Inventors:

Alexey Alexandrovich Lugovskoy - Woburn MA, US
Karl Hanf - Billerica MA, US
You Li - Newton MA, US
Kenneth Simon - Cambridge MA, US
Herman Van Vlijmen - Mechelen, BE

Assignee:

Biogen Idec MA Inc. - Cambridge MA

International Classification:

A61K 39/00

US Classification:

4241331, 5303871

Abstract:

The present invention is based, at least in part, on the discovery that strategic modifications of non-human donor antibody CDR residue(s) can be used to humanize antibodies. Such modifications modulate the 3D structural fit between donor antibody CDRs and human acceptor antibody framework regions that comprise the variable domains of a CDR-grafted antibody. Whereas prior art methods of humanization have relied on making framework substitutions (in which selected human framework residues are backmutated to the corresponding amino acid residue present in the non-human donor antibody), the instant invention is based, at least in part, on a method of humanizing antibodies in which selected CDR residues, and optionally adjacent FR residues, are changed in order to accommodate differences in FR amino acid sequences between donor and acceptor antibodies.

US Patent:

7943742, May 17, 2011

Filed:

Jul 10, 2006

Appl. No.:

11/483190

Inventors:

Shelia M. Violette - Lexington MA, US
Louise A. Koopman - Brookline MA, US
Kenneth J. Simon - Cambridge MA, US
Paul H. Weinreb - Andover MA, US
Herman W. T. van Vlijmen - Mechelen, BE
Jose W. Saldanha - Endfield, GB
Alexey A. Lugovskoy - Woburn MA, US

Assignee:

Biogen Idec MA Inc. - Cambridge MA

International Classification:

C12P 21/08
C07K 16/00
A61K 39/395
C12P 21/04

US Classification:

5303873, 5303881, 53038822, 5303888, 4241331, 4241411, 4241431, 4241551, 435 696, 435 7021

Abstract:

The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize αβintegrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-αβantibodies of the invention. The invention also relates to the identification of differential expression of the integrin αβon the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin αβ.

US Patent:

8153126, Apr 10, 2012

Filed:

Oct 29, 2008

Appl. No.:

12/260510

Inventors:

Shelia M. Violette - Lexington MA, US
Paul H. Weinreb - Andover MA, US
Kenneth J. Simon - Cambridge MA, US
Dean Sheppard - Oakland CA, US
Diane R. Leone - Winchester MA, US

International Classification:

A61K 39/395

US Classification:

4241331, 4241431

Abstract:

Monoclonal antibodies that specifically bind to □v□□. Also included are methods of using these antibodies to treat mammals having or at risk of having □v□6-mediated diseases, or to diagnose □V□6-mediated diseases.

US Patent:

8349324, Jan 8, 2013

Filed:

Dec 1, 2009

Appl. No.:

12/628898

Inventors:

Alexey Alexandrovich Lugovskoy - Woburn MA, US
Karl Hanf - Billerica MA, US
You Li - Newton MA, US
Kenneth Simon - Cambridge MA, US
Herman Van Vlijmen - Mechelen, BE

Assignee:

Biogen Idec MA Inc. - Cambridge MA

International Classification:

A61K 39/395

US Classification:

4241331, 5303871

Abstract:

The present invention is based, at least in part, on the discovery that strategic modifications of non-human donor antibody CDR residue(s) can be used to humanize antibodies. Such modifications modulate the 3D structural fit between donor antibody CDRs and human acceptor antibody framework regions that comprise the variable domains of a CDR-grafted antibody. Whereas prior art methods of humanization have relied on making framework substitutions (in which selected human framework residues are backmutated to the corresponding amino acid residue present in the non-human donor antibody), the instant invention is based, at least in part, on a method of humanizing antibodies in which selected CDR residues, and optionally adjacent FR residues, are changed in order to accommodate differences in FR amino acid sequences between donor and acceptor antibodies.

US Patent:

20060222644, Oct 5, 2006

Filed:

Dec 23, 2004

Appl. No.:

11/021819

Inventors:

Ellen Garber - Cambridge MA, US
Kenneth Simon - Cambridge MA, US
Jose Saldanha - Enfield, GB

Assignee:

Biogen Idec MA Inc. - Cambridge MA

International Classification:

A61K 39/395
C12N 5/06
C07K 16/44

US Classification:

424141100, 530388150, 435328000

Abstract:

This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-β-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the use of the antibodies alone or in combination with chemotherapeutic agent(s) in therapeutic methods.

US Patent:

20110073606, Mar 31, 2011

Filed:

Sep 17, 2010

Appl. No.:

12/807952

Inventors:

Kenneth Simon - Oceanside NY, US

International Classification:

B65D 90/00

US Classification:

220694

Abstract:

An apparatus that allows for safe and secure transport of a tank, canister, container or cylinder in the upright position on the seat in a vehicle, using the three point seat belt mechanism provided in the vehicle. The primary use was directed toward transportation of a 20 pound propane tank. An apparatus consisting of a body and a bracket, attachment or mechanism that holds the seats belts in place around the tank or cylinder. The body comes into contact with the tank and the brackets, attachments or mechanism that are a part of the body, allow for the three point seat belt straps to be placed in a proper position to hold the tank against the car seat in the car. There is also a retaining strap that goes around the value area of the tank to hold it in place.

US Patent:

20110305629, Dec 15, 2011

Filed:

May 17, 2011

Appl. No.:

13/109168

Inventors:

Shelia M. Violette - Lexington MA, US
Louise A. Koopman - Brookline MA, US
Kenneth J. Simon - Cambridge MA, US
Paul H. Weinreb - Andover MA, US
Herman W.T. van Vlijmen - Mechelen, NL
Jose W. Saldanha - Endfield, GB
Alexey A. Lugovskoy - Woburn MA, US

Assignee:

BIOGEN IDEC MA INC. - Cambridge MA

International Classification:

A61K 39/395
A61K 51/10
A61P 35/04
A61K 51/00
A61P 17/06
A61P 35/00

US Classification:

424 149, 4241331, 4241781, 424 111

Abstract:

The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize αβintegrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-αβantibodies of the invention. The invention also relates to the identification of differential expression of the integrin αβon the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin αβ.